These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19222039)

  • 1. Rational design of a minimal and highly enriched CYP102A1 mutant library with improved regio-, stereo- and chemoselectivity.
    Seifert A; Vomund S; Grohmann K; Kriening S; Urlacher VB; Laschat S; Pleiss J
    Chembiochem; 2009 Mar; 10(5):853-61. PubMed ID: 19222039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An efficient route to selective bio-oxidation catalysts: an iterative approach comprising modeling, diversification, and screening, based on CYP102A1.
    Seifert A; Antonovici M; Hauer B; Pleiss J
    Chembiochem; 2011 Jun; 12(9):1346-51. PubMed ID: 21591046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
    Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
    J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altering the regioselectivity of the subterminal fatty acid hydroxylase P450 BM-3 towards gamma- and delta-positions.
    Dietrich M; Do TA; Schmid RD; Pleiss J; Urlacher VB
    J Biotechnol; 2009 Jan; 139(1):115-7. PubMed ID: 18984016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for the properties of two single-site proline mutants of CYP102A1 (P450BM3).
    Whitehouse CJ; Yang W; Yorke JA; Rowlatt BC; Strong AJ; Blanford CF; Bell SG; Bartlam M; Wong LL; Rao Z
    Chembiochem; 2010 Dec; 11(18):2549-56. PubMed ID: 21110374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of selectivity determinants in CYP monooxygenases by modelling and systematic analysis of sequence and structure.
    Seifert A; Pleiss J
    Curr Drug Metab; 2012 Feb; 13(2):197-202. PubMed ID: 22208534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of the stereo-selectivity of styrene epoxidation by cytochrome P450 BM3 using structure-based mutagenesis.
    Huang WC; Cullis PM; Raven EL; Roberts GC
    Metallomics; 2011 Apr; 3(4):410-6. PubMed ID: 21240430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure, electronic properties and catalytic behaviour of an activity-enhancing CYP102A1 (P450(BM3)) variant.
    Whitehouse CJ; Yang W; Yorke JA; Tufton HG; Ogilvie LC; Bell SG; Zhou W; Bartlam M; Rao Z; Wong LL
    Dalton Trans; 2011 Oct; 40(40):10383-96. PubMed ID: 21603690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
    Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH
    Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of a minimal enriched P450 BM3 mutant library for hydroxylation of cyclic and acyclic alkanes.
    Weber E; Seifert A; Antonovici M; Geinitz C; Pleiss J; Urlacher VB
    Chem Commun (Camb); 2011 Jan; 47(3):944-6. PubMed ID: 21079837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A highly active single-mutation variant of P450BM3 (CYP102A1).
    Whitehouse CJ; Bell SG; Yang W; Yorke JA; Blanford CF; Strong AJ; Morse EJ; Bartlam M; Rao Z; Wong LL
    Chembiochem; 2009 Jul; 10(10):1654-6. PubMed ID: 19492389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective hydroxylation of highly branched fatty acids and their derivatives by CYP102A1 from Bacillus megaterium.
    Budde M; Morr M; Schmid RD; Urlacher VB
    Chembiochem; 2006 May; 7(5):789-94. PubMed ID: 16566047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P450 fingerprinting method for rapid discovery of terpene hydroxylating P450 catalysts with diversified regioselectivity.
    Zhang K; El Damaty S; Fasan R
    J Am Chem Soc; 2011 Mar; 133(10):3242-5. PubMed ID: 21341707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P450(BM3) (CYP102A1): connecting the dots.
    Whitehouse CJ; Bell SG; Wong LL
    Chem Soc Rev; 2012 Feb; 41(3):1218-60. PubMed ID: 22008827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel semi-biosynthetic route for artemisinin production using engineered substrate-promiscuous P450(BM3).
    Dietrich JA; Yoshikuni Y; Fisher KJ; Woolard FX; Ockey D; McPhee DJ; Renninger NS; Chang MC; Baker D; Keasling JD
    ACS Chem Biol; 2009 Apr; 4(4):261-7. PubMed ID: 19271725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolved CYP102A1 (P450BM3) variants oxidise a range of non-natural substrates and offer new selectivity options.
    Whitehouse CJ; Bell SG; Tufton HG; Kenny RJ; Ogilvie LC; Wong LL
    Chem Commun (Camb); 2008 Feb; (8):966-8. PubMed ID: 18283351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P450(BM3) on steroids: the Swiss Army knife P450 enzyme just gets better.
    Wong LL
    Chembiochem; 2011 Nov; 12(17):2537-9. PubMed ID: 21998091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation.
    Park SH; Kim DH; Kim D; Kim DH; Jung HC; Pan JG; Ahn T; Kim D; Yun CH
    Drug Metab Dispos; 2010 May; 38(5):732-9. PubMed ID: 20100815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11.
    Vottero E; Rea V; Lastdrager J; Honing M; Vermeulen NP; Commandeur JN
    J Biol Inorg Chem; 2011 Aug; 16(6):899-912. PubMed ID: 21567268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cloning, expression and characterisation of CYP102A7, a self-sufficient P450 monooxygenase from Bacillus licheniformis.
    Dietrich M; Eiben S; Asta C; Do TA; Pleiss J; Urlacher VB
    Appl Microbiol Biotechnol; 2008 Jul; 79(6):931-40. PubMed ID: 18483737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.